Shattuck Labs, Inc. (STTK)
NMS · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 1.0M | 0.00 | 0.00 | 0.00 |
| Operating Income | (10.7M) | (13.4M) | (15.5M) | (16.2M) |
| Net Income | (10.1M) | (12.6M) | (14.8M) | (15.2M) |
| Diluted EPS | $-0.14 | $-0.12 | $-0.13 | $-0.12 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 652K | 1.7M | 5.7M | 1.0M |
| Operating Income | (103.3M) | (92.0M) | (80.6M) | (51.5M) |
| Net Income | (101.9M) | (87.3M) | (75.4M) | (48.8M) |
| Diluted EPS | $-2.41 | $-2.05 | $-1.49 | N/A |